Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Consolidated Net Income: 2021-2025

Historic Consolidated Net Income for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.7 million.

  • InMed Pharmaceuticals' Consolidated Net Income fell 2.92% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 20.58%. This contributed to the annual value of -$8.2 million for FY2025, which is 6.34% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Consolidated Net Income of -$1.7 million as of Q3 2025, which was up 3.43% from -$1.8 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Consolidated Net Income high stood at -$336,591 for Q2 2023, and its period low was -$7.9 million during Q2 2022.
  • In the last 3 years, InMed Pharmaceuticals' Consolidated Net Income had a median value of -$1.8 million in 2025 and averaged -$1.8 million.
  • In the last 5 years, InMed Pharmaceuticals' Consolidated Net Income skyrocketed by 95.72% in 2023 and then crashed by 473.57% in 2024.
  • InMed Pharmaceuticals' Consolidated Net Income (Quarterly) stood at -$4.3 million in 2021, then skyrocketed by 51.01% to -$2.1 million in 2022, then grew by 29.55% to -$1.5 million in 2023, then tumbled by 74.20% to -$2.6 million in 2024, then declined by 2.92% to -$1.7 million in 2025.
  • Its Consolidated Net Income stands at -$1.7 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$2.1 million for Q1 2025.